Search clinical trials for: PK & PD study

Total 125737 results

Q32 Bio Inc.

Not yet recruiting

A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

IgA Nephropathy | Lupus Nephritis (LN) | C3 (Complement Component 3) Glomerulopathy
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

PK/PD Study of SHR-2017 Injection in Patients With Bone Metastases

Patients With Bone Metastases

China
Eilean Therapeutics

Not yet recruiting

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia

AML With Gene Mutations

Australia
Haisco Pharmaceutical Group Co., Ltd.

Recruiting

A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects

Healthy

China
The Third Xiangya Hospital of Central South University

Not yet recruiting

PK/PD Study of Anti-Infective Drugs in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation Treatment (ECMO)

Critical Illness | Extracorporeal Membrane Oxygenation Complication

China
Suzhou Genhouse Bio Co., Ltd.
Shanghai East Hospital; Shandong Tumor Hospital

Recruiting

A Phase I/II Clinical Study to Evaluate The Safety, PK, PD of GH55 in Patients With MAPK Mutant Advanced Solid Tumors

Advanced Solid Tumors With MAPK Signal Pathway Mutant

China
UniQure Biopharma B.V.

Recruiting

Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

Fabry Disease

United States
OriCell Therapeutics Co., Ltd.

Recruiting

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Cardiovascular Diseases | Vascular Diseases | Neoplasms | Immune System Diseases | Neoplasms by Histologic Type | Lymphoproliferative Disorders | Immunoproliferative Disorders | Hematologic Diseases | Hemostatic Disorders | Hemorrhagic Disorders | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood...

United States
Neuracle Science Co., LTD.
Samsung Medical Center; Korea University Anam Hospital; Severance Hospital

Recruiting

A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients

Sudden Sensorineural Hearing Loss | Seneorineural Deafness

Korea, Republic of
iN Therapeutics Co., Ltd.

Recruiting

A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.

Pain | Osteoarthritis | Chronic Pain | Neuropathic Pain | Post Herpetic Neuralgia

Australia
PepGen Inc

Recruiting

Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1 (FREEDOM-DM1)

Myotonic Dystrophy 1

United States, Canada
Agomab Spain S.L.

Recruiting

Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF

IPF

United Kingdom
Amplicon AB

Recruiting

Study to Assess PK, PD, Nicotine Extraction, Palatability, Subjective Effects of Nicotine Pouches - Daily Nicotine Users

Nicotine Use Disorder

Sweden
Intercept Pharmaceuticals

Not yet recruiting

Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy

Biliary Atresia
Sirius Therapeutics Co., Ltd.

Recruiting

A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy Participants

Thrombosis

Australia
Shanghai Henlius Biotech

Recruiting

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

Advanced Solid Tumor

China
Aro Biotherapeutics

Recruiting

Study to Assess the Safety, Tolerability, PK and PD of ABX1100

Healthy

Canada
Qualigen Theraputics, Inc.
Translational Drug Development

Recruiting

Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

Solid Tumor

United States
Peptomyc S.L.

Recruiting

Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC (OMO-103-02)

Metastatic Pancreatic Cancer

Spain
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

Palmoplantar Psoriasis | Genital Psoriasis

United States, Germany, Spain, Italy, Poland, Argentina, Canada
Addpharma Inc.

Recruiting

A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121

Gastro Esophageal Reflux

Korea, Republic of
Empros Pharma AB
CTC Clinical Trial Consultants AB

Recruiting

A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers

Overweight or Obesity

Sweden
Nacuity Pharmaceuticals, Inc.

Recruiting

PK and PD Study of NPI-001 and Cysteamine Bitartrate (INCA)

Cystinosis

Australia
Turgut Ardika PTY LTD

Recruiting

Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy Participants

Healthy

Australia
Agomab Spain S.L.

Recruiting

STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

Fibrostenotic Crohn's Disease

United States, Italy, Poland, Spain, Denmark, Austria, Canada, Germany
ABL Bio, Inc.

Recruiting

This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants

Healthy

United States
Disc Medicine, Inc

Recruiting

Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia

Chronic Kidney Diseases | Anemia of Chronic Kidney Disease

United States
Protalix

Recruiting

A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels

Gout

New Zealand
Chiesi Farmaceutici S.p.A.
ICON plc

Recruiting

Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease (RISE)

Fabry Disease

Japan
The Hospital for Sick Children

Recruiting

Safety and PK-PD Study of Oral L-CIT in Preterm Infants With BPD±PH and NEC

Pulmonary Hypertension | NEC | BPD - Bronchopulmonary Dysplasia

Canada
Haisco Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Clinical Study to Evaluate the Efficacy, Safety and PK/PD Profiles of Anticoagulation of HSK36273 for Injection in Continuous Renal Replacement Therapy Subjects

Renal Replacement Therapy

China
Glycomine, Inc.

Recruiting

24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG

Pmm2-CDG

Spain, Australia, United States
Guangzhou Henovcom Bioscience Co. Ltd.

Recruiting

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension

Parkinson's Disease

United States
Ono Pharmaceutical Co. Ltd

Recruiting

A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

United States
Alexion Pharmaceuticals, Inc.

Recruiting

Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants

Healthy

United Kingdom
GC Biopharma Corp

Recruiting

A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient

Hemophilia

Korea, Republic of
Artcline GmbH
Zentrum für Klinische Studien Jena; CRO Kottmann

Recruiting

Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy (ReActiF-ICE)

Sepsis, Severe

Germany
GC Biopharma Corp

Recruiting

A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients With MPS Ⅱ

Mucopolysaccharidosis II | Hunter Syndrome

Korea, Republic of
Gilead Sciences
Merck Sharp & Dohme LLC

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

Triple Negative Breast Cancer | PD-L1 Positive

United States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

Triple Negative Breast Cancer | PD-L1 Negative

United States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more
AO GENERIUM

Recruiting

A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II

Metabolic Diseases | Mucopolysaccharidosis Type II

Russian Federation
Harbour BioMed (Guangzhou) Co. Ltd.

Not yet recruiting

A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid Tumors

Solid Tumors
Chong Kun Dang Pharmaceutical

Recruiting

A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects

GERD

Korea, Republic of
Duke University
Food and Drug Administration (FDA)

Recruiting

Opportunistic PK/PD Trial in Critically Ill Children (OPTIC) (OPTIC)

Critically Ill | Cardiac Disease | Children, Adult

United States
AL-S Pharma

Recruiting

A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Korea, Republic of, United States, Canada, Germany, Sweden, Belgium
Harbour BioMed (Guangzhou) Co. Ltd.

Not yet recruiting

A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

Solid Tumor
Amicus Therapeutics

Recruiting

A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18 (ROSSELLA)

Glycogen Storage Disease Type II Infantile Onset

United States, Taiwan, France, Germany, Italy, United Kingdom
Simcha IL-18, Inc.
Merck Sharp & Dohme LLC

Recruiting

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Melanoma | Carcinoma | Renal Cell Carcinoma | Cancer | Solid Tumor | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Triple-negative Breast Cancer | MSI-High

United States
Hanmi Pharmaceutical Company Limited

Recruiting

Phase 2 Study to Assess the Safety, PK, and PD in SBS-IF Subjects

Short Bowel Syndrome

Belgium, Korea, Republic of, United States, Germany, Denmark, France, Poland
Pfizer

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6)

Locally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung Cancer

United States, China, Australia, Korea, Republic of, Japan

Search clinical trials for: PK & PD study

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations